The Pro Medicus (ASX:PME) share price is surging 5% on Thursday

This ASX biotech share is having a strong day of trade

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price is surging higher on Thursday. Shares in the Aussie biotech group have climbed more than 5% in a sharp rebound from Wednesday's session.

At the time of writing, the Pro Medicus share price is up 4.05%, trading at $54.71.

Group of medical professionals high five

Image source: Getty Images

What's with the Pro Medicus share price today?

Today's share price move hasn't been sparked by any news or announcements from the Aussie healthcare group. In fact, Pro Medicus hasn't released any ASX announcements at all since September 2.

However, that hasn't stopped investors piling into the company's shares and bidding up the Pro Medicus share price on Thursday.

It's possible today's moves are a rebound after shares in the ASX healthcare informatics group slumped lower yesterday. The company's shares have been under pressure amid broader weakness in the healthcare and technology sectors.

While yesterday had signs of profit-taking after year to date gains above 50%. Any fears of extended losses have subsided for now, however, as momentum has returned to the healthcare group's shares on Thursday.

A rising tide?

There is also the old 'rising tide raises all ships' adage that could be at play. The S&P/ASX 200 Index (ASX: XJO) has added 1.82% at the time of writing in a good day for Aussie investors.

Strong investor sentiment could be playing its part with the Pro Medicus share price roaring back to life after a disappointing day of trade on Wednesday.

It's yet another day of gains in what is shaping up to be a good year for shareholders. Despite somewhat stagnating earlier this year, the company's value has been steadily climbing since May.

Steady gains appear to have been supported by new contract signings including an 8-year, $14 million deal with The University of Vermont.

Foolish takeaway

It looks like the good times just keep on rolling for the Pro Medicus share price. Shares in the ASX biotech have now more than doubled in the last 12 months with gains of 104%.

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »